MARLBOROUGH, Mass., Nov. 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II study, the pivotal trial designed to support SYNERGY™ Stent System approval by the FDA.  EVOLVE II data will be presented in a Late-Breaking Clinical Trial presentation on November 19 at 10:55am CT at the 2014 American Heart Association Scientific Sessions.  The Boston Scientific investor event and webcast, which will include a question and answer session, is scheduled to begin at 1:00 p.m. CT and adjourn at approximately 2:00 p.m. CT.

Speakers will include Keith Dawkins, M.D., executive vice president and chief medical officer, and Kevin Ballinger, senior vice president and global president, interventional cardiology, Boston Scientific, as well as Dean Kereiakes, M.D., principal investigator for EVOLVE II and Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati.

A live webcast of the question and answer session will be available to interested parties via the Boston Scientific website.  Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors.  Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.

This webcast is being hosted by NasdaqOMX.  A replay will be archived and available at www.bostonscientific.com/investors beginning approximately one hour following the completion of the question and answer session.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS
Media:
Denise Kaigler 
508-683-4449 (office)
Corporate Affairs & Communications 
Boston Scientific Corporation 
denise.kaigler@bsci.com

Investors:
Susie Lisa, CFA
508- 683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com 

SOURCE Boston Scientific Corporation